North East and North Cumbria
ICS Formulary
1 Gastro-intestinal system
01-05-02 Corticosteroids
Prednisolone
Formulary
First Choice
See BNF 06:03:02 for formulations
Budesonide
Formulary
Alternative
Budenofalk® (3mg capsules enclosing e/c pellets)
Entocort® (3mg capsules enclosing e/c m/r pellets)
For use on consultant gastroenterologist advice only
Oral Viscous Budesonide
unlicensed
For the treatment of eosinophilic oesophagitis.
0.5mg or 1mg nebule is added to 13ml of syrup and this is then mixed and swallowed.
Orodispersible tablet (Jorveza®)
For the treatment of eosinophilic oesophagitis in adults in line with NICE
Approved for the maintenance of eosinophilic oesophagitis in line with NTAG
9mg MR tablet (Cortiment®)
For induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.
8 week course to be provided by secondary care.
4mg modified-release capsules (Kinpeygo®)
Approved for treating primary IgA nephropathy in line with NICE
NICE TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy
NTAG Treatment Appraisal: Budesonide orodispersible (Jorveza®) for maintenance treatment of eosinophilic oesophagitis
Prednisolone
Formulary
5mg suppositories only
Budesonide
Formulary
2mg foam enema
Equal first choice with hydrocortisone foam enema
Links
Newcastle, North Tyneside, Northumberland & Gateshead - Guidelines for Monitoring of Immune Modifying Drugs (IMDs) in Stable Adult Patients (excluding post transplantation) in Primary and Secondary Care
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
NICE NG129: Crohn’s disease: management
NICE NG130: Ulcerative colitis: management
NICE NG147: Diverticular disease: diagnosis and management
NICE TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy
NTAG Treatment Appraisal: Budesonide orodispersible (Jorveza®) for maintenance treatment of eosinophilic oesophagitis
NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence
Key
Full Site